You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

8 months ago
Bioregnum
R&D

Ex­clu­sive: For­mer Ama­zon Phar­ma­cy ex­ecs back Me­vo, a start­up bring­ing on­line pre­scrib­ing to Brazil

8 months ago
Financing
Health Tech

Ther­at­e­ch­nolo­gies' HIV drug to face sup­ply is­sues in 2025 over third-par­ty fa­cil­i­ty shut­down 

8 months ago
Pharma
FDA+

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

8 months ago
People
Health Tech

No­var­tis’ Kisqali snags FDA ap­proval to re­duce re­cur­rence in pa­tients with ear­ly forms of breast can­cer

8 months ago
Pharma
FDA+

Con­duct­ing tri­als via rou­tine clin­i­cal prac­tice: FDA ex­plains how in new draft guid­ance

8 months ago
R&D
FDA+

CD­MO Serán sets out to build first com­mer­cial fa­cil­i­ty, with a $200M in­vest­ment led by Bain Cap­i­tal

8 months ago
Pharma
Manufacturing

Co­herus warns of lim­it­ed can­cer drug sup­ply due to third-par­ty ‘ca­pac­i­ty con­straints’

8 months ago
Pharma
Manufacturing

Capri­cor ex­pands DMD pact with Nip­pon Shinyaku; Ab­b­Vie’s new eye deal

8 months ago
News Briefing

Cigna sues FTC, call­ing for with­draw­al of 'bi­ased, er­ro­neous' PBM re­port

8 months ago
Pharma
Law

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

8 months ago
People
In Focus

Sun, sur­pris­es and new sum­mits at Eu­rope’s biggest can­cer con­fer­ence

8 months ago
R&D
Pharma

Af­ter land­ing a key win in a com­mon can­cer con­di­tion, Pfiz­er faces a big test in Phase 3

8 months ago
R&D
Pharma

Mer­ck and Dai­ichi’s re­ject­ed HER3 ADC clears a Phase 3 in cer­tain lung can­cers

8 months ago
R&D

Nu­ra Bio rais­es $68M for clin­i­cal tests of SARM1 in­hibitor to po­ten­tial­ly slow or pre­vent nerve de­gen­er­a­tion

8 months ago
Financing
R&D

Em­met Stephen­son gives $150M to City of Hope for pan­cre­at­ic can­cer, cre­at­ing mil­lion-dol­lar re­search prize

8 months ago
Financing
R&D

23andMe heads to ES­MO to tout its two clin­i­cal-stage drugs af­ter scrap­ping dis­cov­ery team

8 months ago
Startups
R&D

Eu­ro­pean reg­u­la­tors for­ti­fy sin­gle-arm tri­al ad­vice, but un­der­score pref­er­ence for place­bo-con­trolled de­signs

8 months ago
FDA+

FDA tells on­col­o­gy com­pa­nies how to run mul­ti-re­gion­al can­cer tri­als with a US ap­proval in mind

8 months ago
R&D
FDA+

FDA ap­proves Lil­ly's eczema drug Ebglyss for mod­er­ate-to-se­vere dis­ease

8 months ago
Pharma
FDA+

Boehringer plans NDA fil­ing for pul­monary fi­bro­sis drug fol­low­ing Phase 3 da­ta

8 months ago
R&D

Roche out­lines com­mer­cial man­u­fac­tur­ing strat­e­gy for GLP-1/GIP as­sets 

8 months ago
Pharma
Manufacturing

BioN­Tech rolls out Phase 2 lung can­cer da­ta as VEGF bis­pecifics take cen­ter stage

8 months ago
R&D

Nu­va­len­t's $350M of­fer­ing; FDA lifts par­tial hold on Zen­tal­is drug

8 months ago
News Briefing
First page Previous page 103104105106107108109 Next page Last page
A service from the Financial Times